COVID-19 Secondary Infections: Hospital Data and Complication Rates

What Is the Prevalence of Bacterial Co-infection in COVID-19 Patients?

The linked ISARIC/WHO CCP‑UK and UKHSA analysis of 173,947 hospital episodes in England found that 5.8% (10,017) of COVID‑19 patients had a bacterial or fungal infection. Pre‑admission (preceding) infections were rare (0.7%) and co‑infections at admission occurred in 1.5% of cases, while secondary infections developed in 3.5% of stays. Blood cultures most often grew Escherichia coli (29.6%) and Staphylococcus aureus (15.2%); lower‑respiratory samples showed S. aureus (22.9%) and Pseudomonas aeruginosa (20.4%). The 28‑day case‑fatality rate for secondary infection stayed at 36%, unchanged over the study period. The work is a preprint and has not yet undergone peer review.

How Common Are Fungal Infections in Hospitalized COVID-19 Patients?

The investigation was a collaboration between the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID‑19 Clinical Characterisation Partnership in the UK (CCP‑UK) and the UK Health Security Agency (UKHSA). ISARIC provides a global platform for rapid data collection during infectious‑disease emergencies, while UKHSA curates national laboratory surveillance data. By merging these two resources, the team could track microbiology results alongside COVID‑19 admissions across English hospitals from January 2020 to October 2021. The study is posted on medRxiv as a preprint, meaning it has not yet been evaluated by independent reviewers.

What Are the Primary Secondary Complications in COVID-19 Hospitalizations?

Researchers linked hospital admission records from the ISARIC/WHO CCP‑UK cohort with UKHSA laboratory databases that capture positive bacterial and fungal specimens. Adults over 18 were included, and infections were categorized as preceding (2–28 days before a positive SARS‑CoV‑2 PCR), co‑infection (within one day of the PCR date), or secondary (2–28 days after). A multi‑step hierarchical algorithm assigned each positive specimen to one of these windows. In total, 173,947 distinct COVID‑19 hospital episodes were analysed, providing a large, nationally representative sample. Because the data are observational, the analysis can describe patterns but cannot prove that the infections caused the outcomes observed.

What Do Secondary Infection Rates Mean for COVID-19 Patients?

A 5.8% infection rate suggests that most COVID‑19 inpatients do not acquire a bacterial or fungal complication, but the minority who do face a substantial risk. Secondary infections, which appeared after the initial COVID‑19 diagnosis, were three times more common than co‑infections, highlighting the vulnerability of patients during prolonged stays or intensive care. The fact that the 28‑day fatality stayed at 36% for those with secondary infection—while it fell in other groups—signals that once a secondary pathogen takes hold, mortality risk remains high despite improvements in COVID‑19 care over time.

What Are the Limitations of This COVID-19 Secondary Infection Study?

Because the analysis is based on routinely collected data, it cannot establish a cause‑and‑effect link between bacterial/fungal infection and death; it only shows an association. The preprint status means the methods and findings have not been vetted by external reviewers, so errors may still exist. Details such as antibiotic prescribing practices, infection severity scores, or exact timing of ICU admission were not captured, limiting insight into how treatment decisions influence outcomes. Finally, the study covers England only, so results may not apply to hospitals with different patient mixes or infection‑control policies.

Why Are Secondary Infection Findings Important for Clinical Care?

Understanding which pathogens dominate COVID‑19‑related infections helps clinicians choose empiric antibiotics more wisely, potentially reducing unnecessary broad‑spectrum use. The prominence of E. coli and S. aureus in blood cultures, and P. aeruginosa in respiratory samples, aligns with known hospital‑acquired organisms, reinforcing the need for vigilant hygiene and ventilation strategies. For patients and families, the data underscore that secondary infections remain a serious complication, so early recognition and targeted therapy are critical. Public‑health officials can use these patterns to allocate resources for microbiology testing and to fine‑tune infection‑prevention guidelines during future respiratory pandemics.

What Are the Future Research Directions for COVID-19 Complications?

The authors plan to submit the manuscript for peer review, which will test the robustness of the linkage algorithm and clarify any confounding factors. Ongoing work aims to integrate antibiotic‑use data, explore outcomes by ICU versus ward setting, and assess whether vaccination status altered infection risk. If the findings hold up, UKHSA may update national surveillance dashboards and issue guidance on antimicrobial stewardship for COVID‑19 patients. Clinicians can watch for updated recommendations in forthcoming WHO and NHS publications.